Adherence and resource use among patients treated with biologic drugs: Findings from BEETLE study

ClinicoEconomics and Outcomes Research

Volumn 6, Issue , 2014, Pages 401-407

  Esposti, Luca Degli ^a   Sangiorgi, Diego ^a   Perrone, Valentina ^b   Radice, Sonia ^b   Perone, Francesco ^c,d   Buda, Stefano ^a  

^a Economics and Outcomes Research   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SCIENTIFIC INSTITUTE   (Italy)

^d Local Health Unit Number 10   (Italy)

Author keywords

Anti TNF alpha; Cost of illness; Therapy adherence

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DRUG COST; DRUG SUBSTITUTION; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTPATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

EID: 84907671338     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S66338     Document Type: Article

References (36)

1. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol. 2000;27(3):613-622.
2. Borman P, Toy GG, Babaoğlu S, Bodur H, Ciliz D, Alli N. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol. 2007;26(3):330-334.
3. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.
4. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am. 1990;16(3):513-537.
5. Lebwohl M. Psoriasis. Lancet. 2003;361(9364):1197-1204.
6. Sieper J, Braun J. New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. Ann Rheum Dis. 2001;60 Suppl 3: iii58-iii61.
7. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden of immune-mediated inflammatory diseases - focusing on work productivity and disability. J Rheumatol Suppl. 2011;88:55-61.
8. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355(7):704-712.
9. Humira (adalimumab) prescribing information. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124. Accessed June 28, 2014.
10. Enbrel (etanercept) prescribing information. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124. Accessed June 28, 2014.
11. Remicade (infliximab) prescribing information. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124. Accessed June 28, 2014.
12. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56(1):13-20.
13. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
14. Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901-913.
15. Markenson JA, Gibofsky A, Palmer WR, et al. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol. 2011;38(7): 1273-1281.
16. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12-S17.
17. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization; 2003.
18. Hughes D, Cowell W, Koncz T, Cramer J; International Society for Pharmacoeconomics and Outcomes Research Economics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health. 2007;10(6):498-509.
19. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1): 44-47.
20. Di Bari M, Balzi D, Roberts AT, et al. Prognostic stratification of older persons based on simple administrative data: development and validation of the “Silver Code,” to be used in emergency department triage. J Gerontol A Biol Sci Med Sci. 2010;65(2):159-164.
21. Ministry of Labour, Health and Social Policies. Annual report on the hospitalization activity. 2005. Available from: http://www.ministerosalute.it/programmazione/sdo/sezDocumenti.jsp?id=148&label=osp. Accessed June 28, 2014.
22. Gonnella JS, Louis DZ, Gozum MVE, Callahan CA, Barnes CA. Disease Staging Clinical and Coded Criteria. Version 5.26. Ann Arbor, MI: Thomson Reuters; 2009.
23. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther. 2008;30(7):1375-1384.
24. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health. 2000;3(6): 417-426.
25. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
26. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335-344.
27. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9(Suppl 6):S136-S143.
28. Punzi L, Matucci Cerinic M, Cantini F, et al. Treatment patterns of anti-TNF agents in Italy: an observational study. Reumatismo. 2011;63(1):18-28.
29. Williams A, Manias E, Walker R. Interventions to improve medication adherence in people with multiple chronic conditions: a systematic review. J Adv Nurs. 2008;63(2):132-143.
30. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol. 2009;36(5):907-913.
31. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol. 2009;27(6):926-934.
32. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol. 2009;36(10):2171-2177.
33. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19(27):4344-4350.
34. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum. 2009;61(5):560-568.
35. Esposito M, Gisondi P, Cassano N, et al. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol. 2013;169(3): 666-672.
36. Schwartzman S, Morgan GJ. Does route of administration affect the outcome of TNF antagonist therapy?Arthritis Res Ther. 2004;6 Suppl 2:S19-S23.